DAGLB
| Official symbol: | DAGLB |
| Full name: | diacylglycerol lipase beta |
| Location: | 7p22.1 |
| Also known as: | KCCR13L, DAGLBETA |
| Entrez ID: | 221955 |
| Ensembl ID: | ENSG00000164535 |
| Summary: | |
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
| Gscore (Amp): | 0.58 | | Gscore (Del): | 0.39 |
|
|
| Recurrently amplified in 4 cancer type(s) | |
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall
|
|
Tissue specific
|
| |
| Total fusion occurrence: | 0 |
|
|
|
| |
|
|
|
| Functional class: | Enzyme |
| JensenLab PubMed score: | 14.47 (Percentile rank: 42.16%) |
| PubTator score: | 4.51 (Percentile rank: 27.10%) |
| Target development/druggability level: | TchemThese targets have activities in ChEMBL or DrugCentral that satisfy the activity thresholds detailed below. |
| Tractability (small molecule): | Discovery PrecedenceTargets with ligands; Targets with crystal structures with ligands |
| Tractability (antibody): | Predicted Tractable - High confidenceTargets located in the plasma membrane; Targets with GO cell component terms plasma membrane or secreted |
